The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHL
Featured:
Martin HutchingsDuring the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Martin Hutchings, Rigshospitalet, Copenhagen, DK. We asked, What are the updated results of brentuximab vedotin + chemotherapy for untreated classical Hodgkin lymphoma (cHL)?
Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHL
In this video, Hutchings reports on the 5-year update from the randomized ECHELON-1 study (NCT01712490) including more than 1,300 patients with newly diagnosed advanced-stage Hodgkin lymphoma. He goes on to discuss efficacy, side effects, including peripheral neuropathy, and follow-up data regarding fertility and secondary malignancies.